Pacer Advisors Inc. Invests $1.87 Million in Semler Scientific Inc. (NASDAQ:SMLR)

Key Points

• Pacer Advisors Inc. has acquired a new stake in Semler Scientific Inc., purchasing 51,768 shares valued at approximately $1,874,000, representing 0.54% of the company.
• Multiple institutional investors have also invested in Semler Scientific, with notable acquisitions exceeding $46 million from Interchange Capital Partners LLC and around $30 million from Capital International Investors.
• Despite recent interest from investors, Semler Scientific's stock has decreased by 6.8%, with a current market cap of $504.71 million and a negative earnings per share of ($0.76).

Pacer Advisors Inc. acquired a new position in Semler Scientific Inc. (NASDAQ:SMLR - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 51,768 shares of the company's stock, valued at approximately $1,874,000. Pacer Advisors Inc. owned approximately 0.54% of Semler Scientific at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of SMLR. Cambridge Investment Research Advisors Inc. grew its stake in shares of Semler Scientific by 10.2% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 6,226 shares of the company's stock worth $225,000 after buying an additional 576 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Semler Scientific by 49,133.3% in the 1st quarter. GAMMA Investing LLC now owns 7,385 shares of the company's stock worth $267,000 after buying an additional 7,370 shares in the last quarter. Wells Fargo & Company MN grew its stake in shares of Semler Scientific by 618.3% in the 4th quarter. Wells Fargo & Company MN now owns 103,465 shares of the company's stock worth $5,587,000 after buying an additional 89,060 shares in the last quarter. Nuveen Asset Management LLC grew its stake in shares of Semler Scientific by 396.9% in the 4th quarter. Nuveen Asset Management LLC now owns 124,548 shares of the company's stock worth $6,726,000 after buying an additional 99,482 shares in the last quarter. Finally, MetLife Investment Management LLC purchased a new position in shares of Semler Scientific in the 4th quarter worth $163,000. 49.37% of the stock is owned by hedge funds and other institutional investors.

Semler Scientific Stock Down 3.9%

NASDAQ SMLR traded down $1.39 during trading on Friday, reaching $34.46. 858,455 shares of the company's stock traded hands, compared to its average volume of 711,868. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.52 and a quick ratio of 0.51. The firm has a market cap of $475.20 million, a price-to-earnings ratio of -13.20 and a beta of 1.34. The company's 50 day simple moving average is $38.02 and its two-hundred day simple moving average is $40.14. Semler Scientific Inc. has a 12-month low of $21.77 and a 12-month high of $81.56.

Semler Scientific (NASDAQ:SMLR - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.76) EPS for the quarter. The business had revenue of $8.84 million for the quarter. Semler Scientific had a negative net margin of 60.69% and a positive return on equity of 19.75%.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Benchmark initiated coverage on shares of Semler Scientific in a research note on Tuesday, July 8th. They issued a "buy" rating and a $101.00 price objective for the company. Maxim Group upgraded shares of Semler Scientific to a "strong-buy" rating and set a $95.00 target price for the company in a report on Wednesday, July 9th. Cantor Fitzgerald assumed coverage on shares of Semler Scientific in a report on Monday, July 28th. They issued an "overweight" rating and a $61.00 target price for the company. Finally, Wall Street Zen lowered shares of Semler Scientific from a "buy" rating to a "sell" rating in a report on Thursday, May 22nd. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $82.00.

Semler Scientific Profile

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition.